Last updated: 24 August 2022 at 4:04pm EST

Kevin Ctang Capital Partner... Net Worth




The estimated Net Worth of Kevin Ctang Capital Partner... is at least $18.2 Million dollars as of 29 November 2021. Kevin Partner owns over 441,290 units of Odonate Therapeutics Inc stock worth over $10,760,886 and over the last 4 years Kevin sold ODT stock worth over $7,475,773.

Kevin Partner ODT stock SEC Form 4 insiders trading

Kevin has made over 8 trades of the Odonate Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Kevin sold 441,290 units of ODT stock worth $1,734,270 on 29 November 2021.

The largest trade Kevin's ever made was selling 2,747,131 units of Odonate Therapeutics Inc stock on 17 November 2021 worth over $5,741,504. On average, Kevin trades about 603,676 units every 61 days since 2020. As of 29 November 2021 Kevin still owns at least 9,607,934 units of Odonate Therapeutics Inc stock.

You can see the complete history of Kevin Partner stock trades at the bottom of the page.



Insiders trading at Odonate Therapeutics Inc

Over the last 7 years, insiders at Odonate Therapeutics Inc have traded over $20,636,060 worth of Odonate Therapeutics Inc stock and bought 10,839,138 units worth $199,522,296 . The most active insiders traders include Capital, Llc Eco R1, Aaron I. Davis, and Kevin Ctang Capital Partner.... On average, Odonate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $444,503. The most recent stock trade was executed by Capital, Llc Eco R1 on 1 December 2021, trading 5,887,610 units of ODT stock currently worth $9,714,557.



What does Odonate Therapeutics Inc do?

Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.



Complete history of Kevin Partner stock trades at La Jolla Pharmaceutical Co and Odonate Therapeutics Inc

Insider
Trans.
Transaction
Total value
Kevin Ctang Capital Partner...
Chief Financial Officer
Sale $1,734,270
29 Nov 2021
Kevin Ctang Capital Partner...
Chief Financial Officer
Buy $1,095,239
27 May 2021
Kevin Ctang Capital Partner...
Chief Financial Officer
Buy $1,578,907
24 May 2021
Kevin Ctang Capital Partner...
Chief Financial Officer
Buy $1,096,774
4 Sep 2020
Kevin Ctang Capital Partner...
Chief Financial Officer
Buy $1,605,727
12 Aug 2020
Kevin Ctang Capital Partner...
Chief Financial Officer
Buy $3,020,283
2 Jun 2020
Kevin Ctang Capital Partner...
Chief Executive OfficerChief Financial Officer
Sale $5,741,504
17 Nov 2021
Kevin Ctang Capital Partner...
Chief Executive OfficerChief Financial Officer
Buy $4,180,885
21 Dec 2020


Odonate Therapeutics Inc executives and stock owners

Odonate Therapeutics Inc executives and other stock owners filed with the SEC include: